SHENZHEN, CHINA and ROCKVILLE, MD, February 1, 2021— HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced the appointment of Leigh MacConell, Ph.D., as Chief Development Officer. Dr. MacConell has over 20 ye

HTD1801 met primary endpoint in Phase 2 trial with statistically significant reduction in liver fat in patients with NASH and diabetes

SHENZHEN, CHINA and ROCKVILLE, MD, October 1, 2020 — HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company with novel treatments for patientswith non-alcoholic steatohepatitis (NASH) and other chronic liver dis